Editorial: The next generation of colloids: Ready for "prime time"?

Anesthesia and Analgesia

Volumn 109, Issue 6, 2009, Pages 1715-1717

  Nussmeier, Nancy A ^a   Searles, Bruce E ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; ELECTROLYTE; FRESH FROZEN PLASMA; GLUCOSE; HETASTARCH; NORMOSOL; PLASMALYTE; RINGER LACTATE SOLUTION; UNCLASSIFIED DRUG; ALBUMINOID; AUTACOID; BIOLOGICAL MARKER; PLASMA SUBSTITUTE;

ACID BASE BALANCE; ANAPHYLAXIS; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL PRACTICE; COLLOID; CORONARY ARTERY BYPASS GRAFT; CRYSTALLOID; EDITORIAL; ELECTROLYTE DISTURBANCE; ERYTHROCYTE; EXTRACORPOREAL CIRCULATION; HEMODILUTION; HEMOSTASIS; HUMAN; ISCHEMIA; KIDNEY FAILURE; LIVER DYSFUNCTION; MORTALITY; OSMOLARITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; BLOOD; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; DRUG EFFECT; EVIDENCE BASED MEDICINE; IMMUNOLOGY; INFLAMMATION; KIDNEY; METABOLISM; METHODOLOGY; NOTE; THROMBOCYTE AGGREGATION; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ALBUMINS; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COLLOIDS; CORONARY ARTERY BYPASS; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HETASTARCH; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY; PLASMA SUBSTITUTES; PLATELET AGGREGATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 73949157572     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181bef685     Document Type: Editorial

References (32)

1. Haynes GH, Havidich JE, Payne KJ. Why the Food and Drug Administration changed the warning label for hetastarch. Anesthesiology 2004;101:801-807
2. Boldt J, Suttner S, Brosch C, Lehmann A, Röhm K, Mengistu A. Cardiopulmonary bypass priming using a high-dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy. Anesth Analg 2009;109:1752-1762
3. Boldt J. Saline versus balanced hydroxyethyl starch: does it matter? Curr Opin Anaesthesiol 2008;21:679-683
4. Cooper JR Jr, Giesecke NM. Hemodilution and priming solutions. In: Gravlee G, Davis R, Stammers A, Ungerleider R, eds. Cardiopulmonary bypass principles and practice. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 2008:411-422
5. Boonstra P, Gu YJ. Priming fluids for cardiopulmonary bypass. In: Kay P, Munch C, eds. Techniques in extracorporeal circulation. 4th ed. London: Arnold, 2004:99-107
6. Galleti PM, Brecher GA. Hematologic problems. In: Galleti PM, Brecher GA, eds. Heart-lung bypass: principles and techniques of extracorporeal circulation. New York, NY: Grune & Stratton, 1962:260-276
7. Peirce EC II. Adjunct techniques-hemodilution. In: Peirce EC, ed. Extracorporeal circulation for open-heart surgery: pathophysiology, apparatus and methods including the special techniques of hypothermia and hyperbaric oxygenation. Springfield, IL: Charles C Thomas, 1969:46-61
8. Reed CC, Clark DK. Fluid balance and selection. In: Reed CC, Clark DK, eds. Cardiopulmonary perfusion. Houston, TX: Texas Medical Press, Inc., 1975:214-217
9. de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001;29:1261-1267
10. Tobias MA. Choice of priming fluids. In: Taylor KM, ed. Cardiopulmonary bypass principles and management. London: Chapman and Hall, 1986:221-248
11. US Food and Drug Administration. Gelatin. Fed Regist 1978;43:14743
12. Cooper JR Jr, Slogoff S. Hemodilution and priming solutions for cardiopulmonary bypass. In: Gravlee GP, Davis RF, Stammers AH, Ungerleider R, eds. Cardiopulmonary bypass principles and practice. 1st ed. Baltimore: Williams & Wilkins, 1993:124-137
13. Frumento R, Bennett-Guerrero E. Prime solutions for extracorporeal circulation. In: Mongero LB, Beck JR, eds. On bypass advanced perfusion techniques. Totowa, NJ: Humana Press, 2008:71-84
14. Barron ME. A systematic review of the comparative safety of colloids. Arch Surg 2004;139:552-563
15. Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA. Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest 2003;123:1853-1857
16. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a metaanalysis of postoperative bleeding. Ann Thorac Surg 2001;72: 527-534
17. Davidson IJ. Renal impact of fluid management with colloids: a comparative review. Eur J Anaesthesiol 2006;23:721-738
18. Davidson IJ. Hydroxyethyl starch 130/0.4: safe in cardiac surgery? Crit Care Med 2008;36:1695- 6; author reply 1696
19. Nuttall GA, Oliver WC. Con: use of colloids in cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:457-459
20. Haynes GR. Fluid management in cardiac surgery: is one hydroxyethyl starch solution safer than another? J Cardiothorac Vasc Anesth 2006;20:916-917
21. Wiedermann CJ. Hydroxyethyl starch-can the safety problems be ignored? Wien Klin Wochenschr 2004;116:583-594
22. Boldt J. Pro: use of colloids in cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:453-456
23. Boldt J. Modern rapidly degradable hydroxyethyl starches: current concepts. Anesth Analg 2009;108:1574-1582
24. Kozek-Langenecker SA. Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology 2005;103:654-660
25. Sakr Y, Payen D, Reinhart K, Sipmann FS, Zavala E, Bewley J, Marx G, Vincent JL. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007;98:216-224
26. Boldt J, Suttner S, Brosch C, Lehmann A, Mengistu A. Influence on coagulation of a potato-derived hydroxethylstarch (HES 130/0.42) and a maize-derived hydroxethylstarch (HES 130/0.4) in patients undergoing cardiac surgery. Br J Anaesth 2009;102: 191-197
27. Kasper S-M, Meinert P, Kampe S, Gorg C, Geisen C, Mehlhorn U, Diefenbach C. Large-dose hydroxyethyl starch 130/0/4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 2003;99:42-47
28. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 2001;15:316-321
29. Gallandat-Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, Bepperling F. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000;47:1207-1215
30. Boldt J, Brosch C, Ducke M, Papsdorf M. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 2007;35:2740-2746
31. Boldt J, Brosch Ch, Röhm K, Papsdorf M, Mengistu A. Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. Br J Anaesth 2008;100:457-464
32. Boldt J, Brosch Ch, Röhm K, Lehmann A, Mengistu A, Suttner S. Is albumin administration in hypoalbuminemic elderly cardiac surgery patients of benefit with regard to inflammation, endothelial activation, and long-term kidney function? Anesth Analg 2008;107:1496-1503